Drug intelligence / Profile preview

HEC122505

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

HEC122505 is an orally administered small molecule drug under development for the treatment of Parkinson's disease. It acts as a selective inhibitor of monoamine oxidase B (MAO-B), an enzyme involved in the breakdown of dopamine in the brain. By inhibiting MAO-B, HEC122505 is intended to increase dopamine levels and alleviate symptoms associated with Parkinson's disease. The drug has demonstrated favorable safety and pharmacokinetic profiles in phase I clinical trials, showing rapid absorption and good tolerability across a range of doses. Development is led by Sunshine Lake Pharma[1][2][3][4].

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on HEC122505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC122505.

Explore the full profile